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Abstract
Objective: To describe the degree of HIV disease progression in infants initiating antiretroviral therapy (ART) by three months of
age in a programmatic setting in South Africa.
Design: This was a programmatic cohort study.
Methods: Electronic and manual data extraction from databases and antiretroviral registers in 20 public clinics in Cape Town and
electronic data extraction from a large ART service at Chris Hani Baragwanath Hospital in Soweto were performed. Records of all
infants initiated on ART by three months of age between June 2007 and September 2010 were extracted. Demographics,
immunological and clinical stage at ART initiation were analyzed descriptively by chi-square, two-sample t-test and Kaplan
Meier methods.
Results: A total of 403 records were identified: 88 in Cape Town and 315 in Soweto. Median age at ART initiation was 8.4
[interquartile range (IQR): 7.29.7] weeks. At ART initiation, 250 infants (62%) had advanced HIV disease (CD4% B25% or
absolute CD4B1500 cells/mm3 or WHO clinical Stage 3 or 4). Median age at ART initiation by site was 10.3 (IQR: 8.211.9)
weeks in Cape Town and 8.6 (IQR: 7.710.0) weeks in Soweto infants (pB0.0001). In Cape Town, 73 infants (83%) had advanced
HIV disease at ART initiation, compared to 177 infants (56%) in Soweto (pB0.0001). On logistic regression, each month increase
in age at ART initiation lowered the odds of initiating ART in an optimal state (OR: 0.56, CI: 0.360.94) and increased the odds of
advanced HIV disease at ART initiation (OR: 1.69, CI: 1.052.71).
Conclusions: ART initiation by three months of age may not adequately prevent disease progression. New emphasis on early
diagnosis and rapid initiation of ART in the first weeks of life are essential to further reduce infant mortality.
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Introduction
Despite a 43% reduction in mother-to-child transmission
(MTCT) of HIV, 390,000 children globally were newly infec-
ted with the virus in 2010 [1]. Of these, 48,000 occurred in
South Africa where the perinatal transmission of HIV was
3.5% [2]. Pooled national data showed that only 54% of
HIV-exposed infants received a HIV DNA polymerase chain
reaction (PCR) test by two months of age in 2010 [3]. Delayed
diagnosis leads to delay in access to antiretroviral therapy
(ART) and subsequent increase in infant morbidity and mor-
tality [4,5]. The Children with HIV Early antiRetroviral therapy
(CHER) trial showed that ART initiation before 12 weeks
of age in infants with CD4]25% and minimal clinical HIV
disease reduced mortality by 75% [4]. Worryingly, however,
19% of the infants screened for CHER (median age: seven
weeks) already had severe CD4 depletion (CD4B25%). A
retrospective review of the South African national infant
death register data demonstrated a peak in early infant mor-
tality due to HIV between two and three months of age
[6]. Similarly, a pooled analysis of sub-Saharan African data
revealed substantial mortality within the first 3 months of life
in perinatally infected infants [7]. These data imply that even
when early infant diagnosis and referral occur, ART ini-
tiation by three months of age may be too late for a signi-
ficant proportion of HIV-infected infants. The current study
compares the pre-ART characteristics of infants who were
successfully initiated on ART by three months of age in Cape
Town and Soweto, and highlights the proportion who had
advanced HIV disease at ART initiation.
Method
In Cape Town, HIV-exposed infants born at Midwife Obstetric
Units were routinely referred to their local clinic for infant
PCR testing at four to six weeks of age; results were given
two to four weeks later and those who were infected were
referred on to a paediatric ART treatment site to initiate ART.
In Soweto (which, as a whole, forms Johannesburg Health
Subdistrict D), prior to 2010, any infant newly diagnosed
with HIV was routinely referred to Chris Hani Baragwanath
Academic Hospital (CHBAH) to initiate ART, since staff at
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other health facilities were not trained to initiate infant
ART prior to the introduction of the paediatric nurse-initiated
ART training programme in 2010. At CHBAH, HIV-positive
mothers were routinely given a referral at neonatal discharge
to return for PCR testing on-site at the Paediatric Wellness
Clinic at four weeks of age. At the follow-up visit two weeks
later, test results were given and ART initiation processes
were initiated on-site. Infants referred for ART from outside
CHBAH would routinely be seen at the Paediatric Wellness
Clinic, and therefore the cases on the Paediatric Wellness
database would have included, as far as possible, all newly
diagnosed infants in Soweto. Acutely ill children who were
diagnosed with HIV during inpatient admission at CHBAH
would not typically appear on the Paediatric Wellness data-
base until after discharge, since they were usually initiated
on ART during their inpatient stay.
Records of all infants initiated on ART by three months of
age between June 2007 and September 2010 were extracted.
Infants who died or were lost to follow-up before ARTcould be
initiated, or who were initiated on ART after three months of
age, were not included. In Cape Town, all primary, secondary
and tertiary public health care facilities providing paedia-
tric ART in the Northern, Eastern, Khayelitsha, Tygerberg,
Drakenstein and Stellenbosch health subdistricts were in-
cluded, along with the Red Cross War Memorial Children’s
Hospital (RXH) in the Western subdistrict. Electronic data
extraction from the Tygerberg Family Clinic for HIV database,
the Red Cross Paediatric HIV database and the Winelands
Paediatric HIV database was performed, with manual data
extraction from antiretroviral registers in the remaining clinics.
In Soweto, electronic data extraction was from the Paedia-
tric Wellness Clinic database at CHBAH, which is run and
maintained by the Perinatal HIV Research Unit. This database
used a data fax system to collect data in real time at each
infant visit. Infants were not primarily research participants.
Demographic characteristics, pre-ART immunological and
clinical stage were recorded. Mortality and loss-to-follow-up
(LTFU) status at date of data extraction were also recorded.
Participants were described as being lost to follow-up if they
had not been seen in the clinic for more than a year.
Advanced HIV disease was defined as WHO clinical stages
3 or 4 or immunodeficiency (CD4% B25% or absolute CD4B
1500 cells/mm3) as per WHO guidelines [8]. Descriptive statis-
tics was performed on continuous variables while chi-square
analysis was used for categorical comparisons. The pre-ART
immunological values were compared using the two-sample
t-test. Time-to-event analysis was performed using Kaplan
Meier methods in which comparisons were made using the
log-rank test. Logistic regression was used to determine
the predictive factors for initiating ART in an optimal clinical
and immunological state (defined as WHO clinical Stage 1 or
2 and normal CD4) and for advanced HIV disease at ART
initiation. Normal CD4 was defined as CD4% ]25% and ab-
solute CD4]1500 cells/mm3. Statistical analyses were perfor-
med using R version 2.10.0 (Bell Laboratories, New Jersey).
Stata version 11.0 (Statacorp, Texas) was used for survival
analysis and MedCalc version 12.2.1 for graphics. Where
data were missing, these individuals were included in the
denominator when percentage was calculated, unless stated
otherwise. This study was approved by the Health Research
Ethics Committees of Stellenbosch University and the Uni-
versities of the Witwatersrand and Cape Town, and was
performed in accordance with the Declaration of Helsinki
(version 2000).
Results
Eighty-eight records were identified in Cape Town and 315
in Soweto (Table 1). Median age at ART initiation was 8.4
[interquartile range (IQR): 7.29.7] weeks. By ART initiation
before three months of age, 250 (62%) infants had advanced
HIV disease (as defined earlier): 73 (83%) in Cape Town and
177 (56%) in Soweto (pB0.0001). Median (IQR) CD4% and
absolute CD4 amongst the 95 infants with WHO clinical
Stage 3 or 4 at ART initiation was 28% (2033%) and 1318
(7401789) cells/mm3, respectively, of whom 56 (59%) had
CD4% B25% or absolute CD4B1500 cells/mm3. Only 22
(5%) infants were initiated on ART before six weeks of age,
of whom six were initiated on ART in an optimal state (as
defined earlier) and nine had advanced HIV disease at ART
initiation. The number of infants initiating ART before six
weeks of age was too small to allow meaningful stratification.
There was no significant gender difference among those with
advanced HIV disease or among those initiating ART in an
optimal state (p0.11 for both).
Median age at ART initiation differed by two weeks with
the Cape Town infants initiated later than the Soweto infants
(pB0.0001). ART regimens were similar at all sites and typi-
cally consisted of stavudine or zidovudine, lamivudine and
lopinavir/ritonavir. Mortality and LTFU outcomes were avail-
able for 653 patient-years of follow-up after ART initiation
(median: 1.6; IQR: 0.92.4 years of follow-up per patient).
Mortality difference by site was marginally significant (p
0.05; Figure 1). LTFU was not significantly different at the
two sites (p0.88; Figure 2). On logistic regression, each
month increase in age at ART initiation lowered the odds of
initiating ART in an optimal state (OR: 0.56, CI: 0.360.94)
and increased the odds of advanced HIV disease at ART
initiation (OR: 1.69, CI: 1.052.71).
The Cape Town group included 14 infants from RXH, a
tertiary hospital in the Western health subdistrict, of whom
10 were WHO clinical Stage 3 and the remainder were WHO
clinical Stage 1 or 2. All 14 initiated on ART after six weeks
of age with CD4% ]25%, although nine had an absolute
CD4B1500 cells/mm3 with a median (IQR) of 1390 (906
1825) cells/mm3. These 14 infants are mentioned separately
because data from the non-tertiary clinics in that health
subdistrict were not available. In the Soweto group, more
than 95% of infants were diagnosed on-site at CHBAH, with
16 additional infants referred from local Soweto clinics to
initiate ART as outpatients.
In Soweto, over 90% of motherinfant pairs received some
form of antiretroviral prevention of mother-to-child transmis-
sion (PMTCT): 264 infants received PMTCT (252 received
single-dose nevirapine; 176 received post-partum zidovu-
dine); 13 infants received no PMTCT (although 8 out of 13
of those mothers did receive PMTCT, which consisted of
single-dose nevirapine for six mothers; post-partum zidovu-
dine for one mother; and three-drug ART for two mothers);
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and 35 infants had no PMTCT status recorded (although
16 out of 35 of those mothers did receive PMTCT, which
consisted of single-dose nevirapine for 16 mothers and post-
partum zidovudine for two mothers). In Cape Town, PMTCT
data were not available for the majority of infants.
Median (IQR) baseline HIV RNA viral load among Cape
Town infants was 365,000 copies/ml (76,0001,800,000
copies/ml), with 36 infants’ data missing. In Soweto, baseline
viral load data was not routinely collected.
Discussion
The current study demonstrates that ART initiation between
8 and 12 weeks of age is associated with advanced HIV
disease at ART initiation. Previous studies have shown that
ART initiation at an advanced stage of HIV disease is asso-
ciated with poorer clinical and immune recovery [9,10].
In the PMTCT programmes of the highest burden countries
in sub-Saharan Africa, a PCR test is performed at six weeks
of age in HIV-exposed infants, followed ideally by HIV
PCR results by 10 weeks of age. If HIV-infected, then pre-
treatment counselling is given with the aim of initiating ART
by three months of age [11]. The results of the current study,
however, suggest that ART initiation by three months of age
may be too late for over half the infants who reach this age.
In addition, recent data have suggested that delaying infant
testing until six weeks of age may lead to significant delays in
ART initiation, high LTFU rates and a significant number of
missed diagnoses [12].
Although more than half of the infants in this study had ad-
vanced disease at ART initiation, there was a noticeable dif-
ference between the two sites. This may be partially explained
by differences in PMTCT programmes between the provin-
ces: the rollout of triple ART from 14 weeks of gestation for
women with CD4B200 cells/mm3 began in 2004, with a single
dose of nevirapine in labour for those with CD4200 cells/
mm3. From February 2008 to July 2010, the South African
Department of Health PMTCT guidelines also provided zido-
vudine monotherapy from 28 weeks of gestation for pregnant
women with CD4200 cells/mm3 [13]. In the Western Cape,
however, zidovudine monotherapy from 28 weeks of gesta-
tion was available from 2006, two years earlier than in
Soweto. This broader coverage resulted in fewer transmis-
sions in the Western Cape [3], which was also influenced by
the lower antenatal HIV prevalence in the Western Cape
province compared to Gauteng province (15% vs. 30%) [14].
Infants infected despite zidovudine PMTCT have rapid
progression of HIV if not treated early with ART [15].
Infections occurring despite peripartum PMTCT may have
occurred in utero. Mortality from in utero infection is more
rapid than peripartum infection [16], and this may explain
part of the difference in degree of disease progression
and corresponding mortality rate by site seen in our study.
Table 1. Characteristics of infants who were successfully initiated on antiretroviral therapy (ART) by three months of age in
the two centres
Total, N403
Cape Town,
N88 Soweto, N315 p*
Demographics
Median age at ART initiation in weeks (IQR) 8.4 (7.29.7) 10.3 (8.211.9) 8.6 (7.710.0) B0.0001
Gender (male/female) 170/209 41/40 129/169 0.24
Pre-ART CD4
Median pre-ART CD4% (IQR) 29% (2337%) 27% (1835%) 28% (2234%) 0.55
Median pre-ART absolute CD4 in cells/mm3 (IQR) 1535 (10562247) 1387 (7172188) 1513 (10592185) 0.20
Number with abnormal pre-ART CD4 (CD4% B25% or absolute CD4
B1500 cells/mm3)
207 (51%) 44 (50%) 163 (52%) 0.77
Missing both CD4% and absolute CD4 data 49 (12%) 4 (5%) 45 (14%) 
WHO at ART initiation
WHO Stage 1 209 (63%) 8 (14%) 201 (74%) B0.0001
WHO Stage 2 25 (8%) 9 (15%) 16 (6%)
WHO Stage 3 72 (22%) 23 (39%) 49 (18%)
WHO Stage 4 23 (7%) 19 (32%) 4 (2%)
Missing WHO clinical stage data 74 29 45 
Summary condition at ART initiation
Number initiating in an ‘‘optimal’’ state (Normal CD4 and WHO 1 or 2)# 106 (26%) 13 (15%) 93 (30%) 0.005
Number missing either CD4 (CD4% or absolute CD4) or WHO stage data# 79 (20%) 33 (38%) 46 (15%) 
Number with advanced HIV disease (pre-ART CD4% B25% or absolute
CD4 B1500 cells/mm3 or WHO Stage 3 or 4)
250 (62%) 73 (83%) 177 (56%) B0.0001
Number missing both CD4 (CD4% and absolute CD4) and WHO
stage data
44 (11%) 0 (0%) 44 (14%) 
*Comparing Cape Town to Soweto; #children were included if either CD4% or absolute CD4 was available. Where both were available, both were
required to be normal; SDstandard deviation; WHOWorld Health Organization; IQRInterquartile range; ARTAntiretroviral therapy.
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Figure 1. Mortality by 24 weeks of age in infants who were successfully initiated on ART before three months of age.*
*Infants who died or were lost to follow-up before ART could be initiated, or who were initiated on ART after three months of age were
not included.
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Figure 2. Loss-to-follow-up at the date of data extraction.*
*Infants who died or were lost to follow-up before ART could be initiated, or who were initiated on ART after three months of age were
not included.
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Despite similar guidelines for the timing of infant PCR testing
in the Western Cape and Gauteng, HIV-infected infants in the
current study started ART significantly later in Cape Town than
in Soweto. This relates to an additional visit at four weeks
post-partum at CHBAH, which was not routinely offered at the
Cape Town sites. While causality is difficult to assign, this
delay was associated with more advanced HIV disease at ART
initiation. The delay was most likely due to the fragmented
distribution of services in Cape Town, where services are
spread across multiple sites and mothers must navigate a
series of referrals to access ART for their infants. For example,
a mother may attend an antenatal clinic at one site; be
referred to another site to deliver; be referred to a third site
for sixth- and tenth-week infant check-ups; and then, if the
infant is HIV-infected, be referred to a fourth site for her
infant to initiate ART. Integration of perinatal, infant PCR
testing and paediatric ART treatment services may reduce
delays in ART initiation for HIV-infected infants and LTFU and
reduce the proportion of infants with advanced HIV disease at
ART initiation.
It is important to advocate for programmatic changes to
achieve early infant diagnosis and rapid initiation of ART to
further reduce HIV-related infant mortality and morbidity.
The addition of a PCR test at birth to national PMTCT
guidelines would identify in-utero-infected infants, who are
at greatest risk of rapid HIV disease progression [16]. Birth
HIV PCR testing has been associated with lower LTFU and
mortality at three months of age in infants infected in utero
[17]. Infants of mothers who did not access adequate
antenatal PMTCT (and may thus have high viral loads) are
particularly at an increased risk of HIV transmission and rapid
disease progression [18]. These ‘‘high-risk’’ infants would benefit
most from selective birth PCR testing and, where PMTCT
programme resources are limited, policy-makers should con-
sider providing a birth PCR test to infants of mothers who did
not access adequate PMTCT. For these selected infants, the
PCR result could be routinely followed-up at the one-week
obstetric follow-up visit. Infants found to be HIV-infected
could be immediately referred for ART initiation. The ab-
solute number of positive birth PCR tests is likely to be
limited, making active tracing by the receiving paediatric ART
clinic feasible.
Limitations
Being a retrospective study, the possibility of confounders
cannot be excluded. In particular, selection bias is possible
since our study was unable to record the infants who died
or were lost to follow-up before ART could be initiated,
and did not include infants who were initiated on ART after
three months of age. The age at PCR testing was not known,
and neither the length of delay between testing and ART
initiation nor the cause of delay was known. While every
effort was made to include all available data sources, the
health districts were selected in a non-random manner and
thus may not accurately represent the national population. In
addition, HIV PCR testing rates were low (36.6% in 2008;
51.8% in 2009 and 59.8% in 2010) [19], and it is possible that
a more complete testing rate may have led to a different
result. After the study, the authors became aware of 30
infants in Soweto and four infants in Cape Town who did not
appear on the respective databases as they were recruited
onto the CHER trial. These infants were all WHO clinical Stage
1 or 2 and had CD4% 25% when they were initiated on
ART before three months of age; thus, their inclusion would
have further increased the differences between sites and
would have marginally reduced the overall proportion of
infants who had advanced HIV disease at ART initiation.
Some data were missing due to deficiencies in routine
programmatic data collection and these may have changed
the findings. The proportion with missing WHO data is high,
and it is possible that those with missing data may be a
biased subgroup. Excluding them from the denominator may
have distorted the calculated percentages, resulting in over-
reporting and increasing the risk of a type 1 error. However, if
those with missing data are added to the denominator, the
percentage of infants with WHO clinical Stage 3 or 4 disease
remains significantly higher in Cape Town than Soweto (48%
vs. 17%), and remains high overall (24%). Data from both
cities included all new infant HIV diagnoses at primary,
secondary and tertiary health care facilities in the respective
health subdistricts, minimizing the likelihood of selection bias
as far as possible. The exception was the Western health sub-
district of Cape Town for which only the RXH database was
included as data from the non-tertiary clinics in that health
subdistrict were not available. However, despite being a
tertiary hospital, the RXH infants were not more sick and, in
fact, had a lower proportion of advanced HIV disease when
compared to Cape Town as a whole (71% vs. 76%) and a
higher proportion initiated in optimal state (28% vs. 18%).
Multiple differences exist between the two study settings
and it may be incorrect to ascribe the difference in HIV
disease stage to the difference in age at ART initiation. The
referral patterns and efficiency of the Cape Town HIV service
may have improved since September 2010, and the differ-
ences in mortality and outcome may have subsequently
lessened. The infants who were initiated on ART within 24
weeks of the date of data extraction would have contributed
less follow-up time to the KaplanMeier analysis, and the
mortality patterns of these children may be significantly
different to the rest of the group. Differences in baseline HIV
RNA viral load between sites may have led to the difference
in HIV disease state; however, viral load data was extremely
sparse because, at the time, viral load was not the standard
of care.
Conclusions
ART initiation by three months of age may be too late to
adequately prevent HIV disease progression. More than half
the infants had advanced HIV disease at the time of ART
initiation despite initiating ART by three months of age. An
on-site system for early infant diagnosis and ART initiation
functioned better than a fragmented service spread across
multiple sites. New emphasis on early diagnosis and rapid
initiation of ART in the first weeks of life are essential to
further reduce infant mortality.
Authors’ affiliations
1Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Stellenbosch
University and Tygerberg Children’s Hospital, Cape Town, South Africa; 2Perinatal
Innes S et al. Journal of the International AIDS Society 2014, 17:18914
http://www.jiasociety.org/index.php/jias/article/view/18914 | http://dx.doi.org/10.7448/IAS.17.1.18914
5
HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg and Chris Hani Baragwanath Hospital, Soweto, South Africa;
3Anova Health Institute, Paarl, Western Cape, South Africa; 4Red Cross War
Memorial Children’s Hospital and the University of Cape Town, Cape Town,
South Africa
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
SI, EL and KO designed the study, guided by MFC and AV. SI, EL, KO, AL, RG,
AJvR, NG, TH and BE collected the data. SI and KO analyzed the data. All
authors contributed to interpretation of results and drafting of the manuscript.
Acknowledgements
The authors are grateful to Marina la Grange for her effort in extracting data
from the Tygerberg Family Clinic for HIV database.
SI is currently receiving a Fogarty International Clinical Research Fellow-
ship grant (#R24-TW007988-01), a pilot research grant (#P30 AI036214-16,
subaward #10304442) from the University of California San Diego Centre for
AIDS Research (CFAR) and a Southern Africa Consortium for Research
Excellence grant (#WTX055734) from the Wellcome Trust.
MFC and AV currently received a grant (#5U01AI069521-01 to 04) from the
National Institute of Allergy and Infectious Diseases (NIAID) through the Inter-
national Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT),
and were funded from a grant (#1U19AI53217-01) from NIAID through the
Comprehensive International Plan for Research in AIDS. MFC also received
funding from grant #USAID 674-A-00-09-00001-00 from United States Agency
for International Development. The recruits on this study were not co-enrolled
in an IMPAACT trial.
Conference presentations
Sections of this data were presented at the 6th International AIDS Society
Conference on HIV Pathogenesis, Treatment and Prevention (IAS), Rome, July
2011 (Abstract CDB413), and at the 5th International Workshop on HIV
Pediatrics, Kuala Lumpur, June 2013 (Abstract P11).
References
1. UNAIDS, World Health Organization, UNICEF. GLOBAL HIV/AIDS RESPONSE
Progress Report 2011: epidemic update and health sector progress towards
universal access. Geneva: WHO Press; 2011.
2. Goga A, Dinh T, Jackson D, for the SAPMTCTE study group. Evaluation of
the effectiveness of the national prevention of mother-to-child transmission
(PMTCT) programme measured at six weeks postpartum in South Africa,
2010. Pretoria: South African Medical Research Council, National Department
of Health of South Africa, and PEPFAR/US Centers for Disease Control and
Prevention; 2012.
3. Sherman G, Lilian R. Early infant diagnosis of HIV infection in South Africa:
2008 to 2010. Johannesburg: National Health Laboratory Service; 2011.
4. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early
antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med.
2008;359(21):223344.
5. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, 3rd,
et al. Effect of combination therapy including protease inhibitors on mortality
among children and adolescents infected with HIV-1. N Engl J Med. 2001;
345(21):15228.
6. Bourne DE, Thompson M, Brody LL, Cotton M, Draper B, Laubscher R, et al.
Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa.
AIDS. 2009;23(1):1016.
7. Marston M, Becquet R, Zaba B, Moulton LH, Gray G, Coovadia H, et al. Net
survival of perinatally and postnatally HIV-infected children: a pooled analysis
of individual data from sub-Saharan Africa. Int J Epidemiol. 2011;40(2):38596.
8. WHO. Antiretroviral therapy of HIV infection in infants and children in
resource-limited settings: towards universal access. Recommendations for a
public health approach [Internet]. 2006 [cited 2013 Mar 13]. Available from:
http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf
9. Fatti G, Bock P, Eley B, Mothibi E, Grimwood A. Temporal trends in baseline
characteristics and treatment outcomes of children starting antiretroviral
treatment: an analysis in four provinces in South Africa, 20042009. J Acquir
Immune Defic Syndr. 2011;58(3):e607.
10. Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al.
Early time-limited antiretroviral therapy versus deferred therapy in South
African infants infected with HIV: results from the children with HIV early
antiretroviral (CHER) randomised trial. Lancet. 2013;382(9904):155563.
11. PEPFAR. AIDS support and technical assistance resources: national
treatment guidelines [Internet]. [cited 2012 Jun 27]. Available from: http://
www.aidstar-one.com/focus_areas/treatment/resources/national_treatment_
guidelines
12. Lilian RR, Kalk E, Technau KG, Sherman GG. Birth diagnosis of HIV infection
in infants to reduce infant mortality and monitor for elimination of mother-to-
child transmission. Pediatr Infect Dis J. 2013;32(10):10805.
13. South African National Department of Health. Policy and guidelines for the
implementation of the PMTCT programme 2008 [Internet]. [cited 2012 Aug 1].
Available from: http://www.info.gov.za/view/DownloadFileAction?id77877
14. South African National Department of Health. The National antenatal
sentinel HIV and syphilis prevalence survey in South Africa, 2010. Pretoria:
South African National Department of Health; 2011.
15. de Souza RS, Gomez-Marin O, Scott GB, Guasti S, O’Sullivan MJ, Oliveira
RH, et al. Effect of prenatal zidovudine on disease progression in perinatally
HIV-1-infected infants. J Acquir Immune Defic Syndr. 2000;24(2):15461.
16. Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al.
Child mortality according to maternal and infant HIV status in Zimbabwe.
Pediatr Infect Dis J. 2007;26(6):51926.
17. Lilian RR, Kalk E, Bhowan K, Berrie L, Carmona S, Technau K, et al. Early
diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks
of age. J Clin Microbiol. 2012;50(7):23737.
18. Ioannidis JP, Tatsioni A, Abrams EJ, Bulterys M, Coombs RW, Goedert JJ,
et al. Maternal viral load and rate of disease progression among vertically
HIV-1-infected children: an international meta-analysis. AIDS. 2004;18(1):
99108.
19. Barron P, Pillay Y, Doherty T, Sherman G, Jackson D, Bhardwaj S, et al.
Eliminating mother-to-child HIV transmission in South Africa. Bull World Health
Organ. 2013;91(1):704.
Innes S et al. Journal of the International AIDS Society 2014, 17:18914
http://www.jiasociety.org/index.php/jias/article/view/18914 | http://dx.doi.org/10.7448/IAS.17.1.18914
6
